CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 300 enrolled
Drug / intervention
Triamcinolone Acetonidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02873026
NCT02873026Phase 3Completed

A Phase 3 Multi-centre Double-masked Randomised Controlled Trial of Adjunctive Intraocular and Periocular Steroid (Triamcinolone Acetonide) Versus Standard Treatment in Eyes Undergoing Vitreoretinal Surgery for Open Globe Trauma.

Moorfields Eye Hospital NHS Foundation Trust·interventional·Posted Aug 19, 2016·Updated Sep 17, 2021

In Brief

A Phase 3 clinical trial evaluating Triamcinolone Acetonide for Eye Injury Trauma. Completed, enrolled 300 participants across 1 site.

Detailed Summary

Eye trauma is a leading cause of blindness and visual impairment. Penetrating injuries of the eye are more likely to result in poor vision and the main cause of this is a scarring response on the retina (proliferative vitreoretinopathy, PVR) The purpose of this study is to investigate the potential of an anti-inflammatory treatment (triamcinolone acetonide) to improve the outcome of surgery in eyes that have suffered severe trauma.There is good evidence from laboratory studies that additional steroid treatment into and around the eye at the time of surgery could reduce scarring by reducing inflammation and improve visual outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 19, 2016
Enrollment StartOct 1, 2014
Primary CompletionMar 31, 2020
Study CompletionJan 31, 2021
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 9.9 years ago

Interventions

Triamcinolone Acetonidedrug

Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated